These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16315400)

  • 1. [significance of PTH (1-84) assay in the management of chronic renal failure and the current status and future of the treatment of renal osteopathy].
    Akizawa T; Akiba T; Inaba M; Shigematsu T; Martin KJ
    Clin Calcium; 2005 Nov; 15(11):136-159. PubMed ID: 16315400
    [No Abstract]   [Full Text] [Related]  

  • 2. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 3. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiology and treatment of renal osteodystrophy].
    Ionova D
    Vutr Boles; 1985; 24(6):23-9. PubMed ID: 3913143
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of renal osteopathy in patients with chronic dialysis].
    Kiss D; Brunner FP
    Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target levels for serum phosphorus and parathyroid hormone.
    Qunibi W; Kalantar-Zadeh K
    Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
    [No Abstract]   [Full Text] [Related]  

  • 8. Skeletal resistance to parathyroid hormone as a background abnormality in uremia.
    Fukagawa M; Iwasaki Y; Kazama JJ
    Nephrology (Carlton); 2003 Oct; 8 Suppl():S50-2. PubMed ID: 15012692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure].
    Weglarska J; Ziółkowska H; Pańczyk-Tomaszewska M; Sieniawska M
    Pediatr Pol; 1995 Dec; 70(12):1011-5. PubMed ID: 8649939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum and renal osteodystrophy in chronic uremia.
    Berland Y; Grandvuillemin M; Charhon S; Olmer M
    Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of renal osteodystrophy.
    Sakhaee K
    Semin Nephrol; 1992 Mar; 12(2):101-8. PubMed ID: 1561490
    [No Abstract]   [Full Text] [Related]  

  • 12. Dialysis osteomalacia and aluminum toxicity: a form of renal osteodystrophy.
    Felsenfeld AJ
    ANNA J; 1985 Jun; 12(3):189-91. PubMed ID: 3848318
    [No Abstract]   [Full Text] [Related]  

  • 13. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
    Cantor T; Sci B
    Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic value of PTH total kit for estimation of bone turnover in children with chronic renal failure].
    Ziółkowska H; Roszkowska-Blaim M
    Przegl Lek; 2006; 63 Suppl 3():149-52. PubMed ID: 16898516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hexa-calcium-hexa-sodium-hepta-citrate hydrate complex for prophylaxis and treatment of renal osteopathy in chronic hemodialysis].
    Albert FW; Schmidt U; Schäfer K
    Med Welt; 1973 Feb; 24(5):185-7. PubMed ID: 4805391
    [No Abstract]   [Full Text] [Related]  

  • 17. III. Clinical algorithms on renal osteodystrophy.
    Nephrol Dial Transplant; 2000; 15 Suppl 5():39-57. PubMed ID: 11073276
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The advantage of measurement of intact PTH in the prediction of clinical response and calcium metabolism after subtotal parathyroidectomy for renal osteodystrophy.
    Barth RH; Cheigh JS; Sullivan JF; Chami J; Suthanthiran M; Stubenbord WT; Stenzel KH; Rubin AL
    Trans Am Soc Artif Intern Organs; 1983; 29():124-8. PubMed ID: 6673220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum procollagen type I carboxyterminal propeptide in CAPD and hemodialysis patients.
    Gerakis A; Apostolou T; Bagiatoudi G; Tzouganatou A; Margellos V; Nikolopoulou N; Billis A
    Perit Dial Int; 1996; 16 Suppl 1():S309-11. PubMed ID: 8728213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.